3D Medicines (Sichuan) Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-31
RECRUITING4
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO100%
Delay Index: of 6 active trials registered more than a year ago, 6 have moved their primary completion (readout) date by more than 6 months since first registration (median +48.0 months). See all sponsors →
Open 3D Medicines (Sichuan) Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Lenvatinib + Envafolimab NCT05024214 |
P1/2 | Recruiting | Solid Tumors; Non-small Cell Lung Cancer | 170 | 2026-12 (+38 mo) |
| Envafolimab+Lenvatinib NCT05112991 |
P2 | Recruiting | Advanced Endometrial Cancer | 108 | 2026-12 (+35 mo) |
| KN035 NCT03667170 |
P2 | Active, not recruiting | Solid Tumor | 188 | 2026-12-30 (+90 mo) |
| Envafolimab NCT04891198 |
P2 | Recruiting | Solid Tumor | 126 | 2027-08-30 (+58 mo) |
| Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection NCT06123754 |
P3 | Recruiting | Non-small Cell Lung Cancer | 390 | 2027-12-30 (+24 mo) |
| Envafolimab plus Gemcitabine&Cisplatin NCT04910386 |
P2 | Not yet recruiting | Biliary Tract Neoplasms | 126 | 2029-06 (+48 mo) |